Outcome of a Triple Inner Branched Aortic Arch Stentgraft. A Prospective, Multicenter Registry.
triple_branch
1 other identifier
observational
30
1 country
1
Brief Summary
Outcome of a triple inner branched aortic arch stentgraft. A prospective, mulitcenter registry.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 2, 2022
CompletedFirst Posted
Study publicly available on registry
September 7, 2022
CompletedStudy Start
First participant enrolled
February 9, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 31, 2027
September 13, 2023
September 1, 2023
3.9 years
September 2, 2022
September 11, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Mortality
30 days after intervention
feasibility in terms of cannulation and stentgrafting of the three branches
During intervention
Stroke
30 days after intervention
Secondary Outcomes (5)
Morbidity
during the follow up period of 3 year
Endoleaks Type I and III
during intervention and the follow up period of 3 year
Longterm mortality
during the follow up period of 3 year
Patency rate of branches
during the follow up period of 3 year
Stroke
during the follow up period of 3 year
Interventions
New findings regarding treatment planning and management of patients with aortic arch pathologies.
Eligibility Criteria
Study participants will be recruited from patients presenting to participating hospitals with aortic pathology and meeting inclusion and exclusion criteria.
You may qualify if:
- years or older
- Presence of Aortic arch pathology
- Treatment planned with triple inner branch from Terumo Aortic
- Availability of the patients during the follow up period
- Informing patients about the study and providing written informed consent
You may not qualify if:
- Women of childbearing age
- Patients under 18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Muenster University Hospital
Münster, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Alexander Oberhuber, MD, PhD
Department of Vascular and Endovascular Surgery University Hospital Münster
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Univ.-Prof. Dr. med.
Study Record Dates
First Submitted
September 2, 2022
First Posted
September 7, 2022
Study Start
February 9, 2023
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
March 31, 2027
Last Updated
September 13, 2023
Record last verified: 2023-09